PDF(Pubmed)
Abstract：
Stroke is accounted as the second-most mortality and adult disability factor in worldwide, while causes the bleeding promptly and lifetime consequences. The employed functional recovery after stroke is highly variable, allowing to deliver proper interventions to the right stroke patient at a specific time. Accordingly, the multidisciplinary nursing team, and the administrated drugs are major key-building-blocks to enhance stroke treatment efficiency. Regarding the healthcare team, adequate continuum of care have been declared as an integral part of the treatment process from the pre-hospital, in-hospital, to acute post-discharge phases. As a curative perspective, drugs administration is also vital in surviving at the early step and reducing the probability of disabilities in later. In this regard, nanotechnology-based medicinal strategy is exorbitantly burgeoning. In this review, we have highlighted the effectiveness of current clinical care considered by nursing teams to treat stroke. Also, the advancement of drugs through synthesis of miniaturized nanodrug formations relating stroke treatment is remarked. Finally, the remained challenges toward standardizing the healthcare team and minimizing the nanodrugs downsides are discussed. The findings ensure that future works on normalizing the healthcare nursing teams integrated with artificial intelligence technology, as well as advancing the operative nanodrugs can provide value-based stroke cares.
摘要：
中风是全球第二大死亡率和成人残疾因素。而造成及时出血和终生后果。中风后所采用的功能恢复是高度可变的，允许在特定时间对正确的中风患者进行适当的干预。因此，多学科护理团队，服用的药物是提高中风治疗效率的主要关键组成部分。关于医疗团队，从院前开始，充分的连续护理已被宣布为治疗过程的组成部分，在医院,急性放电后阶段。从治疗的角度来看，药物管理对于早期生存和减少后期残疾的可能性也至关重要。在这方面,以纳米技术为基础的医疗策略正在蓬勃发展。在这次审查中,我们强调了护理团队考虑的当前临床护理治疗卒中的有效性.此外，通过与中风治疗相关的微型化纳米药物形成的合成，药物的进步被指出。最后,讨论了标准化医疗团队和最小化纳米药物缺点的仍然存在的挑战。这些发现确保了未来致力于规范与人工智能技术集成的医疗保健护理团队，以及推进手术纳米药物可以提供基于价值的中风护理。
